Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Ovid Therapeutics Inc.

Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics to Present Multiple Posters Supporting Its Pipeline Programs Targeting Neuronal Hyperexcitability at the American Epilepsy Society 2024 Annual Meeting
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics to Host Investor Event
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with Vigabatrin
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics to Present at Upcoming September Investor Conferences
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics Appoints Dr. Amanda Banks, Experienced Biotech Leader & Physician as Chief Development Officer
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics to Present at Upcoming August Investor Conferences
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
eNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant Seizures
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics Reports on Takeda’s Announcement of Phase 3 Topline Study Results for Soticlestat
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.